succinic acid mono-{1-[7-chloro-1-(4-chlorophenyl)-2-(4-cyanobenzyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yloxymethyl]cyclopropylmethyl}ester | 1202804-16-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: succinic acid mono-{1-[7-chloro-1-(4-chlorophenyl)-2-(4-cyanobenzyl)-3-oxo-2,3-dihydro-1H-isoindol-1-yloxymethyl]cyclopropylmethyl}ester
• 英文别名: US8618158, Ncl-00016659；4-[[1-[[7-chloro-1-(4-chlorophenyl)-2-[(4-cyanophenyl)methyl]-3-oxoisoindol-1-yl]oxymethyl]cyclopropyl]methoxy]-4-oxobutanoic acid
• CAS: 1202804-16-7
• 化学式: C₃₁H₂₆Cl₂N₂O₆
• 分子量: 593.463
• InChiKey: KVYQKFCGNUBIIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  41
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  117
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• New Therapeutic Agents
  申请人：Golding Bernard Thomas

  公开号：US20110224274A1

  公开（公告）日：2011-09-15

  A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.

  式（I）的化合物或式（II）的化合物或其药学上可接受的盐，其中R1-R7和X如描述中所定义，并且这些化合物在治疗中的使用，特别是在治疗癌症或作为MDM2蛋白与p53相互作用的抑制剂。
• THERAPEUTIC AGENTS
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US20140194486A1

  公开（公告）日：2014-07-10

  A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.

  一种式子为(I)的化合物或式子为(II)的化合物或其药学上可接受的盐，其中R1-R7和X的定义如说明书中所述，并且这些化合物在治疗中的使用，特别是在治疗癌症或作为MDM2蛋白与p53相互作用的抑制剂。
• NEW THERAPEUTIC AGENTS
  申请人：Cancer Research Technology Limited

  公开号：EP2960233B1

  公开（公告）日：2019-10-30
• US9358222B2
  申请人：——

  公开号：US9358222B2

  公开（公告）日：2016-06-07
• [EN] NEW THERAPEUTIC AGENTS<br/>[FR] NOUVEAUX AGENTS THÉRAPEUTIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2009156735A2

  公开（公告）日：2009-12-30

  A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.